You are here

INVOKANA® monotherapy demonstrated significantly greater reductions in systolic blood pressure (BP) vs placebo at 26 weeks1,2

Secondary Endpoint: Adjusted Mean Change in Systolic BP From Baseline at 26 Weeks (mm Hg)


Reductions in systolic blood pressure: INVOKANA® monotherapy vs placeboReductions in systolic blood pressure: INVOKANA® monotherapy vs placebo

 

  • INVOKANA® 100 mg difference from placebo: –3.7 mm Hg (95% CI: –5.9, –1.6; P <0.001)
  • INVOKANA® 300 mg difference from placebo: –5.4 mm Hg (95% CI: –7.6, –3.3; P <0.001)

INVOKANA® is not indicated as an antihypertensive treatment.

SELECT IMPORTANT SAFETY INFORMATION FROM PRESCRIBING INFORMATION

  • INVOKANA® results in an osmotic diuresis, which may lead to reductions in intravascular volume. In clinical studies, the incidence of volume depletion–related adverse reactions was 2.3% and 3.4% with INVOKANA® 100 mg and 300 mg, respectively, vs 1.5% in comparator groups. The risk of these adverse events was increased in patients with impaired renal function (eGFR 30 to <60 mL/min/1.73 m2), elderly patients, and patients on loop diuretics1
  • Patients’ volume status should be assessed and corrected, as necessary, before and during treatment with INVOKANA®1

Study Design

The efficacy and safety of INVOKANA® monotherapy were assessed in subjects with type 2 diabetes mellitus who were inadequately controlled with diet and exercise. In this 26-week, double-blind, placebo-controlled study, 584 patients were randomized to receive placebo (n=192), INVOKANA® 100 mg (n=195), or INVOKANA® 300 mg (n=197). Mean baseline A1C values were, respectively, 7.97%, 8.06%, and 8.01%. The primary endpoint was the change in A1C from baseline to week 26. Prespecified secondary endpoints included change in fasting plasma glucose, change in percent body weight, and change in systolic blood pressure.1,2

Learn about SAFETY

See the results of INVOKANA® VS JANUVIA®, VS GLIMEPIRIDE, in PATIENTS WITH RENAL IMPAIRMENT, and in OLDER PATIENTS.

References: 1. INVOKANA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372-382.